Universität des Saarlandes

uni-saarland.de

Total trials

65

Active

14

Phase 3

6

Total enrollment

159,062

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Pembrolizumab2
Cisplatin1
cisplatin + 5-fluorouracil1
Alternative medications: carboplatin + 5-fluorouracil1
Alternative medications: carboplatin1
R-miniCHOP + Acalabrutinib1
R-miniCHOP1
Lenvatinib1
durvalumab1
Chemotherapy1
Recompensation1

Next readouts

  • 2025-12-31
  • 2026-01
  • 2027-03
  • 2028-04
  • 2032-12

Top conditions

  • Chronic Heart Failure2
  • Acute Decompensated Heart Failure2
  • Obesity2
  • Injury2
  • Cognitive Impairment2
  • Parkinson´s Disease2
  • Parkinson Disease2
  • Covid192

Frequently asked questions about Universität des Saarlandes

How many clinical trials does Universität des Saarlandes have on ClinicalTrials.gov?
Universität des Saarlandes is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
How many of Universität des Saarlandes's trials are in Phase 3?
6 of Universität des Saarlandes's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does Universität des Saarlandes focus on?
Universität des Saarlandes's most-studied conditions on ClinicalTrials.gov are Chronic Heart Failure, Acute Decompensated Heart Failure, Obesity, Injury, Cognitive Impairment.
When are Universität des Saarlandes's next clinical trial readouts?
Universität des Saarlandes has 5 upcoming primary-completion readouts tracked here; the soonest is “Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure”, expected around 2025-12-31.